Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice

Gabriele Schilling, Alena Savonenko, Michael L. Coonfield, Johanna L. Morton, Esther Vorovich, Alexa Gale, Christopher Neslon, Ning Chan, Michelle Eaton, David Fromholt, Christopher A Ross, David R. Borchelt

Research output: Contribution to journalArticle

Abstract

The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological, and genetic interventions ameliorate these abnormalities. As previously reported for the R6/2 mouse model of HD, housing mice in enriched environments improved the motor skills of N171-82Q mice. However, life expectancy was not prolonged. Significant improvements in motor function, without prolonging survival, were also observed in N171-82Q mice treated with Coenzyme Q10 (CoQ10, an energy metabolism enhancer). Several compounds were not effective in either improving motor skills or prolonging life, including Remacemide (a glutamate antagonist), Celecoxib (a COX-2 inhibitor), and Chlorpromazine (a prion inhibitor); Celecoxib dramatically shortened life expectancy. We also tested whether raising cellular antioxidant capacity by co-expressing high levels of wild-type human Cu/Zn superoxide dismutase 1 (SOD1) was beneficial. However, no improvement in motor performance or life expectancy was observed. Although we would argue that positive outcomes in mice carry far greater weight than negative outcomes, we suggest that caution may be warranted in testing Celecoxib in HD patients. The positive outcomes achieved by CoQ10 therapy and environmental stimuli point toward two potentially therapeutic approaches that should be readily accessible to HD patients and at-risk family members.

Original languageEnglish (US)
Pages (from-to)137-149
Number of pages13
JournalExperimental Neurology
Volume187
Issue number1
DOIs
StatePublished - May 2004

Fingerprint

coenzyme Q10
Celecoxib
Huntington Disease
Transgenic Mice
Pharmacology
Phenotype
Life Expectancy
Motor Skills
Excitatory Amino Acid Antagonists
Genetic Engineering
Cyclooxygenase 2 Inhibitors
Prions
Chlorpromazine
Energy Metabolism
Antioxidants
Weights and Measures
Survival
Therapeutics

Keywords

  • Coenzyme Q10
  • Drug trial
  • Environmental enrichment
  • HD-N171-82Q transgenic mice
  • Huntington's disease
  • Remacemide hydrochloride

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

Schilling, G., Savonenko, A., Coonfield, M. L., Morton, J. L., Vorovich, E., Gale, A., ... Borchelt, D. R. (2004). Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Experimental Neurology, 187(1), 137-149. https://doi.org/10.1016/j.expneurol.2004.01.003

Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. / Schilling, Gabriele; Savonenko, Alena; Coonfield, Michael L.; Morton, Johanna L.; Vorovich, Esther; Gale, Alexa; Neslon, Christopher; Chan, Ning; Eaton, Michelle; Fromholt, David; Ross, Christopher A; Borchelt, David R.

In: Experimental Neurology, Vol. 187, No. 1, 05.2004, p. 137-149.

Research output: Contribution to journalArticle

Schilling, G, Savonenko, A, Coonfield, ML, Morton, JL, Vorovich, E, Gale, A, Neslon, C, Chan, N, Eaton, M, Fromholt, D, Ross, CA & Borchelt, DR 2004, 'Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice', Experimental Neurology, vol. 187, no. 1, pp. 137-149. https://doi.org/10.1016/j.expneurol.2004.01.003
Schilling, Gabriele ; Savonenko, Alena ; Coonfield, Michael L. ; Morton, Johanna L. ; Vorovich, Esther ; Gale, Alexa ; Neslon, Christopher ; Chan, Ning ; Eaton, Michelle ; Fromholt, David ; Ross, Christopher A ; Borchelt, David R. / Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. In: Experimental Neurology. 2004 ; Vol. 187, No. 1. pp. 137-149.
@article{c78dcf87795c440097ec6de87336fd7e,
title = "Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice",
abstract = "The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological, and genetic interventions ameliorate these abnormalities. As previously reported for the R6/2 mouse model of HD, housing mice in enriched environments improved the motor skills of N171-82Q mice. However, life expectancy was not prolonged. Significant improvements in motor function, without prolonging survival, were also observed in N171-82Q mice treated with Coenzyme Q10 (CoQ10, an energy metabolism enhancer). Several compounds were not effective in either improving motor skills or prolonging life, including Remacemide (a glutamate antagonist), Celecoxib (a COX-2 inhibitor), and Chlorpromazine (a prion inhibitor); Celecoxib dramatically shortened life expectancy. We also tested whether raising cellular antioxidant capacity by co-expressing high levels of wild-type human Cu/Zn superoxide dismutase 1 (SOD1) was beneficial. However, no improvement in motor performance or life expectancy was observed. Although we would argue that positive outcomes in mice carry far greater weight than negative outcomes, we suggest that caution may be warranted in testing Celecoxib in HD patients. The positive outcomes achieved by CoQ10 therapy and environmental stimuli point toward two potentially therapeutic approaches that should be readily accessible to HD patients and at-risk family members.",
keywords = "Coenzyme Q10, Drug trial, Environmental enrichment, HD-N171-82Q transgenic mice, Huntington's disease, Remacemide hydrochloride",
author = "Gabriele Schilling and Alena Savonenko and Coonfield, {Michael L.} and Morton, {Johanna L.} and Esther Vorovich and Alexa Gale and Christopher Neslon and Ning Chan and Michelle Eaton and David Fromholt and Ross, {Christopher A} and Borchelt, {David R.}",
year = "2004",
month = "5",
doi = "10.1016/j.expneurol.2004.01.003",
language = "English (US)",
volume = "187",
pages = "137--149",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice

AU - Schilling, Gabriele

AU - Savonenko, Alena

AU - Coonfield, Michael L.

AU - Morton, Johanna L.

AU - Vorovich, Esther

AU - Gale, Alexa

AU - Neslon, Christopher

AU - Chan, Ning

AU - Eaton, Michelle

AU - Fromholt, David

AU - Ross, Christopher A

AU - Borchelt, David R.

PY - 2004/5

Y1 - 2004/5

N2 - The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological, and genetic interventions ameliorate these abnormalities. As previously reported for the R6/2 mouse model of HD, housing mice in enriched environments improved the motor skills of N171-82Q mice. However, life expectancy was not prolonged. Significant improvements in motor function, without prolonging survival, were also observed in N171-82Q mice treated with Coenzyme Q10 (CoQ10, an energy metabolism enhancer). Several compounds were not effective in either improving motor skills or prolonging life, including Remacemide (a glutamate antagonist), Celecoxib (a COX-2 inhibitor), and Chlorpromazine (a prion inhibitor); Celecoxib dramatically shortened life expectancy. We also tested whether raising cellular antioxidant capacity by co-expressing high levels of wild-type human Cu/Zn superoxide dismutase 1 (SOD1) was beneficial. However, no improvement in motor performance or life expectancy was observed. Although we would argue that positive outcomes in mice carry far greater weight than negative outcomes, we suggest that caution may be warranted in testing Celecoxib in HD patients. The positive outcomes achieved by CoQ10 therapy and environmental stimuli point toward two potentially therapeutic approaches that should be readily accessible to HD patients and at-risk family members.

AB - The HD-N171-82Q (line 81) mouse model of Huntington's disease (HD), expresses an N-terminal fragment of mutant huntingtin (htt), loses motor function, displays HD-related pathological features, and dies prematurely. In the present study, we compare the efficacy with which environmental, pharmacological, and genetic interventions ameliorate these abnormalities. As previously reported for the R6/2 mouse model of HD, housing mice in enriched environments improved the motor skills of N171-82Q mice. However, life expectancy was not prolonged. Significant improvements in motor function, without prolonging survival, were also observed in N171-82Q mice treated with Coenzyme Q10 (CoQ10, an energy metabolism enhancer). Several compounds were not effective in either improving motor skills or prolonging life, including Remacemide (a glutamate antagonist), Celecoxib (a COX-2 inhibitor), and Chlorpromazine (a prion inhibitor); Celecoxib dramatically shortened life expectancy. We also tested whether raising cellular antioxidant capacity by co-expressing high levels of wild-type human Cu/Zn superoxide dismutase 1 (SOD1) was beneficial. However, no improvement in motor performance or life expectancy was observed. Although we would argue that positive outcomes in mice carry far greater weight than negative outcomes, we suggest that caution may be warranted in testing Celecoxib in HD patients. The positive outcomes achieved by CoQ10 therapy and environmental stimuli point toward two potentially therapeutic approaches that should be readily accessible to HD patients and at-risk family members.

KW - Coenzyme Q10

KW - Drug trial

KW - Environmental enrichment

KW - HD-N171-82Q transgenic mice

KW - Huntington's disease

KW - Remacemide hydrochloride

UR - http://www.scopus.com/inward/record.url?scp=11144358364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144358364&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2004.01.003

DO - 10.1016/j.expneurol.2004.01.003

M3 - Article

C2 - 15081595

AN - SCOPUS:11144358364

VL - 187

SP - 137

EP - 149

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 1

ER -